Clearside Biomedical Stock News

Clearside Biomedical CLSD +38%. Cellectis (CLLS) +13%. Orphazyme ORPH -37%. Aesthetic Medical International (AIH) -19%.

Check these three biotech penny stocks out for your watchlist The post Top Biotech Penny Stocks to Buy Now? 3 to Watch in March  appeared first on Penny Stocks to Buy, Picks, News and Information | P

Clearside Biomedical CLSD +30% on Q4 results.Pearson PSO +21% on report Apollo considering making offer for education company.Lazydays Holdings (LAZY) +19%. 4D pharma (LBPS) +18%

Gainers Excellon Resources Inc. (NYSE: EXN ) rose 133.7% to $2.29 in pre-market trading after jumping around 13% on Thursday. Marygold Companies (NYSE: MGLD ) rose 107.4% to $4.50 in pre-market trading after dropping 21% on Thursday. Paramount Gold Nevada Corp. (NYSE: PZG ) rose 48% to $1.17 in pre-market trading after jumping 14% on Thursday. Tanzanian Gold Corporation (NYSE: TRX ) rose 37.8% to $0.5500 in pre-market trading. Hycroft Mining Holding Corporation (NASDAQ: HYMC ) rose 32% to $1.98 in pre-market trading following a 138% surge on Thursday. Clearside Biomedical, Inc. (NASDAQ: CLSD ) rose 25.9% to $1.70 in pre-market trading after the company reported better-than-expected Q4 results. Lazydays Holdings, Inc.. (NASDAQ: LAZY ) rose 16.3% to $20.78 in pre-market trading. Lazydays reported fourth-quarter FY21 sales growth of 64.1% year-on-year, to $322.54 million. Altamira Therapeutics Ltd. (NASDAQ: CYTO ) shares rose 15.7% to $0.80 in pre-market trading. Alto Ingredients, Inc. (NASDAQ: ALTO ) rose 15.7% to $6.76 in pre-market trading after the company reported better-than-expected Q4 sales results.

Benzinga''s “After-Hours Movers & News” highlights the biggest movers of the day. The information on the price action is collected using Benzinga Pro''s Movers tool. Benzinga Pro users can cross-reference the Movers tool with the Benzinga Pro News tool to identify potential news catalysts moving stocks. See Also: Markets Have Mixed Day Of Trading As Russia-Ukraine Ceasefire Talks Go Nowhere Movers Lucria Health (NASDAQ: LHDX ) +16.86%: Reported net revenue of $61.1 million for the fourth quarter of 2021, representing approximately 300% growth over the last quarter. Recorded full-year revenue of $93.1 million for 2021 Clearside Biomedical (NASDAQ: CLSD ) +34%: Reported quarterly earnings of $0.31 per share, which beat the analyst consensus estimate of $0.16 by … Full story available on Benzinga.com

The shares of Clearside Biomedical <>, a biopharmaceutical company focused on eye disease, have added ~22% in the post-market Thursday after the company’s Q4 2021 financials…

Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q4 2021 Results - Earnings Call Transcript

Clearside Biomedical press release (CLSD): Q4 GAAP EPS of $0.31 beats by $0.16.Revenue of $25.7M (+256900.0% Y/Y) beats by $8.26M.

- XIPERE ® -Related Milestones Generated $20 Million in Non-Dilutive Funding in Q4 2021 -

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 244.44% and 95.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for th

Clearside Biomedical (NASDAQ:CLSD) is scheduled to announce Q4 earnings results on Thursday, March 10th, after market close.The consensus EPS Estimate is $0.21 (+250.0% Y/Y) and…

ALPHARETTA, Ga., March 01, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the

In last trading session, Clearside Biomedical Inc. (NASDAQ:CLSD) saw 0.4 million shares changing hands with its beta currently measuring 1.98. Company’s recent per share price level of $1.59 trading at $0.13 or 8.90% at ring of the bell on the day assigns it a market valuation of $96.12M. That closing price of CLSD’s stock is … Clearside Biomedical Inc. (NASDAQ:CLSD) Is Down -13.11% Over The Past 30 Days: Is There Trouble Ahead? Read More »

ALPHARETTA, Ga., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its fourth quarter and full year 2021 financial results will be reported on Thursday, March 10, 2022 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.